117 related articles for article (PubMed ID: 10777223)
21. Cervical Cancer Screening of Adolescents and Young Women: Further Evidence Shows a Lack of Clinical Value.
Campaner AB; Fernandes GL
J Pediatr Adolesc Gynecol; 2021 Feb; 34(1):6-11. PubMed ID: 33130243
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of high grade squamous intraepithelial lesions (HSIL) and invasive cervical cancer in patients with atypical squamous cells of undetermined significance (ASCUS) from cervical pap smears.
Limpvanuspong B; Tangjitgamol S; Manusirivithaya S; Khunnarong J; Thavaramara T; Leelahakorn S
Southeast Asian J Trop Med Public Health; 2008 Jul; 39(4):737-44. PubMed ID: 19058614
[TBL] [Abstract][Full Text] [Related]
23. Distribution of cervical lesions in young and older women.
Díaz Del Arco C; Jiménez Ayala B; García D; Sanabria C; Fernández Aceñero MJ
Diagn Cytopathol; 2019 Jul; 47(7):659-664. PubMed ID: 31184808
[TBL] [Abstract][Full Text] [Related]
24. Cervical cancer screening programme in Finland with an example on implementing alternative screening methods.
Anttila A; Nieminen P
Coll Antropol; 2007 Apr; 31 Suppl 2():17-22. PubMed ID: 17600933
[TBL] [Abstract][Full Text] [Related]
25. The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer.
Nygård JF; Skare GB; Thoresen SØ
J Med Screen; 2002; 9(2):86-91. PubMed ID: 12133929
[TBL] [Abstract][Full Text] [Related]
26. Some aspects of cervical screening in southern New Zealand; the situation before implementation of the national cervical cancer prevention programme.
Chang AR
Cytopathology; 1993; 4(2):67-76. PubMed ID: 8485313
[TBL] [Abstract][Full Text] [Related]
27. High-grade squamous intraepithelial lesion in women aged <30 years has a prevalence pattern resembling low-grade squamous intraepithelial lesion.
Vale DB; Westin MC; Zeferino LC
Cancer Cytopathol; 2013 Oct; 121(10):576-81. PubMed ID: 23765869
[TBL] [Abstract][Full Text] [Related]
28. Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.
Simonella LM; Lewis H; Smith M; Neal H; Bromhead C; Canfell K
BMC Infect Dis; 2013 Mar; 13():114. PubMed ID: 23452957
[TBL] [Abstract][Full Text] [Related]
29. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
[TBL] [Abstract][Full Text] [Related]
30. Impact of human papillomavirus vaccination on rates of abnormal cervical cytology and histology in young New Zealand women.
Innes CR; Williman JA; Simcock BJ; Hider P; Sage M; Dempster-Rivett K; Lawton BA; Sykes PH
N Z Med J; 2020 Jan; 133(1508):72-84. PubMed ID: 31945044
[TBL] [Abstract][Full Text] [Related]
31. Cervical cancer in New Zealand: national and regional trends.
Cox B; Borman B
N Z Med J; 1994 Aug; 107(984):323-6. PubMed ID: 8072727
[TBL] [Abstract][Full Text] [Related]
32. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,
Bratti MC; Rodríguez AC; Schiffman M; Hildesheim A; Morales J; Alfaro M; Guillén D; Hutchinson M; Sherman ME; Eklund C; Schussler J; Buckland J; Morera LA; Cárdenas F; Barrantes M; Pérez E; Cox TJ; Burk RD; Herrero R
Rev Panam Salud Publica; 2004 Feb; 15(2):75-89. PubMed ID: 15030652
[TBL] [Abstract][Full Text] [Related]
33. [Mass screening for cervical cancer. A one-year registration of cervical cytological tests].
Bjørge T; Gunbjørud AB; Langmark F; Skare GB; Thoresen SO
Tidsskr Nor Laegeforen; 1994 Jan; 114(3):341-5. PubMed ID: 8191435
[TBL] [Abstract][Full Text] [Related]
34. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.
Kitchener HC; Almonte M; Thomson C; Wheeler P; Sargent A; Stoykova B; Gilham C; Baysson H; Roberts C; Dowie R; Desai M; Mather J; Bailey A; Turner A; Moss S; Peto J
Lancet Oncol; 2009 Jul; 10(7):672-82. PubMed ID: 19540162
[TBL] [Abstract][Full Text] [Related]
35. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
36. A review of cervical cancer occurrences in New Zealand 2008-2012.
Hider P; Dempster-Rivett K; Williman J; Dempster-Rivett M; Sadler L; McLeod M; Miller A; Sykes P
N Z Med J; 2018 Mar; 131(1472):53-63. PubMed ID: 29565936
[TBL] [Abstract][Full Text] [Related]
37. Comparison of cervical cytological screening results between postmenopausal and elderly women.
Cakmak B; Köseoğlu DR
Turk Patoloji Derg; 2014; 30(1):38-42. PubMed ID: 24448705
[TBL] [Abstract][Full Text] [Related]
38. Invasive cervical cancer and screening: what are the rates of unscreened and underscreened women in the modern era?
Subramaniam A; Fauci JM; Schneider KE; Whitworth JM; Erickson BK; Kim K; Huh WK
J Low Genit Tract Dis; 2011 Apr; 15(2):110-3. PubMed ID: 21263352
[TBL] [Abstract][Full Text] [Related]
39. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
40. Results of delayed triage by HPV testing and cytology in the Norwegian Cervical Cancer Screening Programme.
Haldorsen T; Skare GB; Ursin G; Bjørge T
Acta Oncol; 2015 Feb; 54(2):200-9. PubMed ID: 24957553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
